Caffeine for apnea of prematurity and brain development at 11 years of age by Kelly, C.E. et al.
RESEARCH ARTICLE
Caffeine for apnea of prematurity and brain development
at 11 years of age
Claire E. Kelly1,2,, Wenn Lynn Ooi1,2, Joseph Yuan-Mou Yang2,3,4, Jian Chen2, Chris Adamson2,
Katherine J. Lee1,5,6, Jeanie L. Y. Cheong1,7,8, Peter J. Anderson1,9, Lex W. Doyle1,6,7,8 &
Deanne K. Thompson1,2,6,10
1Victorian Infant Brain Studies, Murdoch Children’s Research Institute, Melbourne, Australia
2Developmental Imaging, Murdoch Children’s Research Institute, Melbourne, Australia
3Department of Neurosurgery, The Royal Children’s Hospital, Melbourne, Australia
4Neuroscience Research, Murdoch Children’s Research Institute, Melbourne, Australia
5Clinical Epidemiology & Biostatistics Unit, Murdoch Children’s Research Institute, Melbourne, Australia
6Department of Paediatrics, The University of Melbourne, Melbourne, Australia
7Department of Neonatal Services, The Royal Women’s Hospital, Melbourne, Australia
8Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Australia
9Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Melbourne, Australia
10Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
Correspondence
Claire Kelly, Victorian Infant Brain Studies
(VIBeS), Murdoch Children’s Research
Institute, The Royal Children’s Hospital, 50




This work was supported by the National
Health and Medical Research Council of
Australia (Project Grants No. 237117 and No.
108706; Program Grant No. 606789; Centre
of Research Excellence No. 1060733;
Fellowship No. 1081288 to PJA, No.
1127984 to KJL, No. 1141354 to JLYC and
No. 1085754 to DKT). This work was also
generously supported by The Royal Children’s
Hospital Foundation (Grant no. RCH1000)
devoted to raising funds for research at The
Royal Children’s Hospital, as well as the
Murdoch Children’s Research Institute, the
Royal Children’s Hospital, Department of
Paediatrics at The University of Melbourne
and the Victorian Government’s Operational
Infrastructure Support Program
Received: 8 July 2018; Accepted: 10 July
2018
Annals of Clinical and Translational
Neurology 2018; 5(9): 1112–1127
doi: 10.1002/acn3.628
Abstract
Objective: Caffeine therapy for apnea of prematurity has been reported to
improve brain white matter microstructure at term-equivalent age, but its long-
term effects are unknown. This study aimed to investigate whether caffeine
affects (1) brain structure at 11 years of age, and (2) brain development from
term-equivalent age to 11 years of age, compared with placebo. Methods: Pre-
term infants born ≤1250 g were randomly allocated to caffeine or placebo.
Magnetic resonance imaging (MRI) was performed on 70 participants (33 caf-
feine, 37 placebo) at term-equivalent age and 117 participants (63 caffeine, 54
placebo) at 11 years of age. Global and regional brain volumes and white mat-
ter microstructure were measured at both time points. Results: In general, there
was little evidence for differences between treatment groups in brain volumes
or white matter microstructure at age 11 years. There was, however, evidence
that the caffeine group had a smaller corpus callosum than the placebo group.
Volumetric brain development from term-equivalent to 11 years of age was
generally similar between treatment groups. However, there was evidence that
caffeine was associated with slower growth of the corpus callosum, and slower
decreases in axial, radial, and mean diffusivities in the white matter, particularly
at the level of the centrum semiovale, over time than placebo. Interpretation:
This study suggests any benefits of neonatal caffeine therapy on brain structure
in preterm infants weaken over time and are not clearly detectable by MRI at
age 11 years, although caffeine may have long-term effects on corpus callosum
development.
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Introduction
Caffeine is used to treat cessation of breathing in infants
born preterm (apnea of prematurity).1 The Caffeine for
Apnea of Prematurity (CAP) randomized controlled clini-
cal trial established that caffeine has many benefits, and no
harmful effects, on clinically important outcomes in infants
born preterm and low birthweight.1 Benefits included
reduced rates of lung injury (bronchopulmonary dys-
plasia), retinopathy of prematurity and surgery for patent
ductus arteriosus, and increased rates of survival free of
major neurodevelopmental disabilities at 18–21 months of
age.1,2 The effects of caffeine were attenuated when the
children were older, but caffeine was still associated with
reduced rates of developmental coordination disorder at
5 years of age,3 and improved motor outcomes, including
manual dexterity and balance, at 5 and 11 years of age.4,5
The mechanism by which caffeine improves neurode-
velopmental outcomes in preterm infants is not clear.2
Several animal studies have reported that caffeine has
beneficial effects on the brain, but many others warn of
adverse effects.6 In a subgroup of participants from the
CAP trial, caffeine was associated with improved white
matter (WM) microstructure in preterm infants at
approximately term-equivalent age (38–44 weeks’ gesta-
tional age), which may explain how caffeine improved
early neurodevelopmental outcomes.7 However, it is not
known whether this improvement to brain structure per-
sists or weakens in the long-term.
The primary aim of this study was to investigate the
relationship between neonatal caffeine treatment and
brain structure at 11 years of age in a subgroup of the
CAP trial, including the structure of both global brain
regions and specific brain regions involved in motor func-
tion, given the previously reported benefit of caffeine on
long-term motor outcomes in the overall CAP trial.5 The
secondary aim was to investigate the relationship between
neonatal caffeine treatment and longitudinal brain devel-
opment from term-equivalent to 11 years of age.
Materials and Methods
Participants
The CAP trial enrolled 2006 infants with birthweights
500–1250 g, who were randomly allocated to caffeine or
placebo.1,2,4,5,7 Randomization was stratified according to
study center. A subgroup (n = 199) of the infants
enrolled in the CAP trial, who were cared for at the Royal
Women’s Hospital (RWH), Melbourne, is relevant to this
study. Two of the 199 infants were excluded due to con-
genital abnormalities (craniosynostosis and Klinefelter
syndrome). One hundred and seventy-two children (87%
of the children recruited at RWH) were followed up at
11 years of age, along with an additional five children
who were originally enrolled through other centers. Of
these, 118 children had magnetic resonance imaging
(MRI). One child was excluded from all subsequent anal-
yses because of dental braces that compromised image
quality. This left a maximum of 117 children (63 allo-
cated to caffeine and 54 allocated to placebo) who were
included in this study for the primary aim.
Of the 199 infants cared for at the RWH, 70 (33 caffeine,
37 placebo) had MRI at term-equivalent age, including
structural MRI, with 28 (15 caffeine, 13 placebo) of those
also having diffusion MRI, as previously reported.7 All of
the term-equivalent and 11-year MRI data were included in
the secondary aim of the current study.
Ethics approval for recruitment and follow up was
granted by the Human Research Ethics Committee at the
RWH and written informed parental consent was neces-
sary for participation at each follow up.
Data collection at age 11 years
Children underwent 3 Tesla MRI (Siemens Magnetom Trio-
Tim syngo) at 11 years of age at the Royal Children’s Hospi-
tal, Melbourne. T1 images were acquired: repetition time
(TR)/echo time (TE) 1950/2.24 msec, 0.9 mm isotropic vox-
els, field of view (FOV) 230 9 221 mm and flip angle 9
degrees. Diffusion images were acquired via two sequences:
(1). TR/TE 7500/89 msec, FOV 240 9 240 mm, 2.5 mm iso-
tropic voxels, b-value 1000 sec/mm2, 25 diffusion-weighted
gradient directions, five b = 0 sec/mm2 volumes; (2). TR/TE
8000/112 msec, FOV 240 9 240 mm, 2.5 mm isotropic vox-
els, b-value = 3000 sec/mm2, 45 diffusion-weighted gradient
directions, six b = 0 sec/mm2 volumes. All children had both
of the diffusion sequences, but one child in the caffeine group
did not complete the second (b = 3000 sec/mm2) sequence.
Brain volumes
Volumes were generated from the T1 images. The vol-
umes of the intracranial cavity, total brain tissue and
cerebrospinal fluid were calculated using Statistical Para-
metric Mapping (SPM; version 12).8 The volume, surface
area and thickness of the cortical gray matter (GM), WM
volume and brainstem volume were calculated using Free-
Surfer (version 5.3).9–13 Subcortical and deep nuclear GM
volumes [thalamus, basal ganglia nuclei, hippocampus
and amygdala] were calculated using the Functional MRI
of the Brain Software Library’s (FSL’s) Integrated Regis-
tration and Segmentation Tool (FIRST).14 Cerebellum
volume was calculated using SPM’s Spatially Unbiased
Infra-tentorial template (SUIT; version 3.0).15,16 Area and
thickness of the corpus callosum were calculated using
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our previously described software pipeline,17,18 which
divided the corpus callosum into six subregions; genu,
rostral body, anterior mid-body, posterior mid-body, isth-
mus, and splenium.19 Imaging outputs were visually
examined and manually edited as required.
Whole-brain white matter microstructure
Whole brain WM microstructure was analyzed using:
 FSL’s (version 5.0.9) Tract-Based Spatial Statistics
(TBSS).20 This involved analyzing the b = 1000 sec/
mm2 sequence. Processing steps were: motion and eddy
current distortion correction; diffusion tensor fitting to
generate fractional anisotropy (FA), and axial (AD),
radial (RD), and mean (MD) diffusivity images; align-
ment of all participants’ images to a study-specific tem-
plate; generation of a tract skeleton. Despite being
commonly used, TBSS has methodological limitations,
including that the metrics generated can be influenced
by factors other than WM microstructure.21 A comple-
mentary analysis using a more sophisticated WM mod-
eling strategy was therefore carried out.
 MRtrix’s (version 3) fixel-based analysis.22 This
involved analyzing the b = 3000 sec/mm2 sequence. All
recommended steps were followed. Fixel-based analysis
enables investigation of the density and cross-section of
WM fiber populations across the whole brain, thus
providing metrics that are more specific to the WM
microstructural environment compared with TBSS.22
White matter tractography
We reconstructed the corpus callosum, pyramidal sensorimo-
tor, and cerebellar motor tracts (Fig. 1A). This involved
drawing regions of interest on the diffusion images
(b = 3000 sec/mm2 sequence) and using a probabilistic fiber
orientation distribution-based computer algorithm to recon-
struct the tracts (Tournier et al. Improved probabilistic
streamlines tractography by second order integration over
fiber orientation distributions. Proceedings of the International
Society for Magnetic Resonance in Medicine 2010;1670). Fol-
lowing tractography reconstructions, we calculated average
FA, AD, RD, and MD of each of the tracts for every partici-
pant. When tracts were reconstructed using manually drawn
regions of interest, we assessed intra-rater reliability using
intra-class correlation coefficients, which were all ≥0.88, sug-
gesting high intra-rater reliability.
Data collection for longitudinal analyses
At term-equivalent age, we acquired brain T1-, T2- and
diffusion images during infants’ sleep without sedation
using a 1.5 Tesla MRI (General Electric Signa, GE Medi-
cal Systems) at the Royal Children’s Hospital, Melbourne,
as detailed previously.7
Based on the T1 and T2 images, we generated volumes
of the intracranial cavity, cortical GM, WM, deep nuclear
GM, cerebellum, brainstem, and hippocampus. We used
software specifically designed for neonatal images,23,24 or
manual delineation for the hippocampus.25 These data
were used to analyze brain volumetric development.
Using the neonatal T1 and diffusion images, we calcu-
lated the area of, and diffusion tensor values (FA, AD,
RD, and MD) within, the corpus callosum and its six
subregions, as previously described.19 These data were
used to analyze corpus callosum development.
In our previous study at term-equivalent age, we calcu-
lated diffusion tensor values from within manually drawn
regions of interest.7 Three regions (one in the anterior,
one in the central and one in the posterior WM) were
placed bilaterally on both an inferior brain slice at the
level of the mid-thalamus, and a superior brain slice at
the level of the centrum semiovale, that is, a total of 12
regions per participant.7 To enable a longitudinal analysis,
we drew the same regions on the 11-year diffusion
images, for the subset of participants with diffusion
images at both time points (Fig. 1B). This left us with
diffusion values (FA, AD, RD, MD) from 12 regions per
participant per time point. Intra-rater reliability for the
manually drawn 11-year regions was high (all intra-class
correlations ≥0.8, except FA within the right superior
central region [0.71] and AD within the right inferior
posterior region [0.77]).
Statistical analyses
Cross-sectional analysis at age 11 years (primary
aim)
For the whole-brain analyses, we compared cortical GM
surface area, thickness, and volume between treatment
groups using FreeSurfer’s Query, Design, Estimate and
Contrast (QDEC).26 We compared WM diffusion tensor
values (derived from TBSS) between treatment groups
using FSL’s randomize, with 5000 permutations and
threshold-free cluster enhancement.27 We compared fiber
density and cross-section (derived from the fixel-based
analysis) between treatment groups using connectivity-
based fixel enhancement.28 These analyses were adjusted
for age and sex, and corrected for multiple comparisons
using the false discovery rate method (for QDEC) or the
family-wise error rate method (for TBSS and fixel-based
analyses).
Global and regional volume and WM microstructure
measures were compared between treatment groups using
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separate linear regression models, with adjustment for age
and sex (Stata version 14). Models were fitted using gen-
eralized estimating equations to account for correlations
between data from multiple births, which represent a
large proportion of our sample (Table 1). Some outcomes
were measured in both brain hemispheres, in which case
we included data from both hemispheres in a single
model, and instead of allowing for correlations between
data from multiple births, we allowed for correlations
between data from individuals, which we expected to be
more important. There was little evidence for any interac-
tions between group and hemisphere, so the interaction
terms were removed and results are reported combined
across hemispheres.
Longitudinal analysis (secondary aim)
We compared the rate of change in the global and regio-
nal volume and WM microstructural measures from
term-equivalent to 11 years of age between the caffeine
and placebo groups using separate mixed effects models
(Stata version 14). Models included a fixed effect of age
and group, a random effect to allow for the repeated
observations within individuals, and adjustment for sex.
Age-by-group interactions were included. The diffusion
values from regions of interest were measured in both
brain hemispheres at both time points, and values from
both hemispheres were analyzed using a single model that
included a fixed effect of hemisphere. There was little evi-
dence of any interactions between group, age and hemi-
sphere, so these interaction terms were removed and
results are reported combined across hemispheres.
For both aims, all the results were very similar before
and after adjustment for total intracranial volume, so
unadjusted results have been reported. Given the influ-
ence that bronchopulmonary dysplasia,29 major neonatal
brain injuries30 and socioeconomic status31 can have on
brain development in preterm-born children, we also con-
ducted three separate sensitivity analyses: (1) adjusting for
bronchopulmonary dysplasia; (2) excluding the two chil-
dren in our sample who had major neonatal brain injury
(one had intraventricular hemorrhage (IVH) grade 3 and
one had both IVH grade 3 and cystic periventricular
leukomalacia (PVL)); (3) adjusting for maternal educa-
tion level at birth.
Given the large number of comparisons performed, the
analyses with global and regional volumes and WM
microstructure measures were interpreted based on the




Baseline characteristics were similar between participants
in this study in the caffeine (n = 63) and placebo
(n = 54) groups, except fewer participants in the caffeine
group had bronchopulmonary dysplasia and treatment
for a patent ductus arteriosus than in the placebo group
(Table 1). This is consistent with the findings of the over-
all CAP trial.1
There was little evidence that cognitive and motor
outcomes at 11 years of age differed between the caf-
feine (n = 63) and placebo (n = 54) participants in this
study (Table 1). This is in contrast to the results of the
overall CAP trial (total 920 participants), which found
that the caffeine group had better motor outcomes at
11 years of age than the placebo group.5 However, the
magnitudes of the differences observed in motor scores
in our subset (Table 1) were similar to those reported
for the CAP trial overall,5 suggesting that this difference
in study results is most likely due to a lack of power
in our substudy rather than systematic differences in
the substudy population.
Of the seven children included in this study who had
cerebral palsy at age 11 years (Table 1), none had cystic
PVL or IVH grade 3 or 4 in the neonatal period.
Figure 1. Illustration of some of the data generated for this study. (A) Tractography performed using the 11-year diffusion images. Top row: the
pyramidal sensorimotor tracts. The corticospinal tract (left) was reconstructed using seed regions in the pons and inclusion regions in the posterior
limb of the internal capsule. The somatosensory tract (right) was reconstructed using seed regions in the medial lemniscus, inclusion regions in
the thalamus and the combined pericentral cortices (precentral, paracentral, and postcentral cortices), and exclusion regions in the corticospinal
tract portion of the pons. Middle row: the cerebellar motor tracts. The cerebellar-thalamo-cortical tract (left) was reconstructed using seed regions
in the dentate nucleus and inclusion regions in the decussation of the superior cerebellar peduncle, and the contralateral red nucleus, thalamus,
and prefrontal cortex. The cortico-ponto-cerebellar tract (right) was reconstructed using seed regions in the middle cerebellar peduncle, inclusion
regions in the contralateral cerebral peduncle, anterior limb of the internal capsule and prefrontal cortex, and exclusion regions in the decussation
of the superior cerebellar peduncle and medial lemniscus. Bottom row: the corpus callosum tracts, reconstructed using automatically
generated17,18 seed regions in the corpus callosum, with the addition of exclusion regions at the brainstem, cerebral peduncle and thalamus. (B)
Regions of interest drawn on the 11-year diffusion images. Six regions were placed on a single superior brain slice at the level of the centrum
semiovale (left) and six regions were placed on a single inferior brain slice at the level of the mid-thalamus (right). These regions of interest were
intended to reproduce the regions of interest drawn on the neonatal diffusion images, to enable a comparison of white matter microstructure
between the time points. The neonatal regions of interest are shown in Figure 1 of our previous publication.7
1116 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Caffeine and the Brain in Childhood C. E. Kelly et al.
Radiologists reviewed the MRI of these seven children at
age 11 years, and reported that none of these children had
features on their MRI that warranted clinical follow up.
Perinatal characteristics were similar between the
n = 117 participants included in this study and the
remaining n = 85 participants from the RWH who were
excluded from this study (Table S1). Perinatal characteris-
tics of our subset (n = 117) were also similar to those
previously reported for the overall CAP cohort
(n = 920).5
Table 1. Summary of the perinatal and 11-year characteristics by treatment group.
Characteristic Caffeine n = 63 Placebo n = 54 Mean difference (95% CI) P-value
Around birth1
Birth weight in grams 960 (188) 935 (184) 26 (43, 94) 0.46
Gestational age at birth in weeks 27.7 (1.7) 27.4 (1.7) 0.3 (0.3, 0.9) 0.36
Male sex, n (%) 28 (44.4) 30 (55.6) OR 0.6, 95% CI 0.3, 1.3 0.23
Multiple births, n (%) 21 (33.3) 16 (29.6) OR 1.2, 95% CI 0.5, 2.6 0.67
Cystic periventricular leukomalacia, n (%) 0 (0.0) 1 (1.9) NA NA
Intraventricular hemorrhage grade 3/4, n (%) 0 (0.0) 2 (3.7) NA NA
Bronchopulmonary dysplasia, n (%) 18 (28.6) 33 (61.1) OR 0.3, 95% CI 0.1, 0.6 0.001
Patent ductus arteriosus, n (%) 12 (19.1) 22 (40.7) OR 0.3, 95% CI 0.1, 0.8 0.01
Corrected postmenstrual age at MRI in weeks 40.7 (1.1)3 40.9 (1.4)4 0.1 (0.9, 0.6) 0.71
Mother completed post-secondary school education, n (%) 25 (41.0)7 18 (33.3) OR 1.4, 95% CI 0.6, 3.0 0.40
At 11 years2
Corrected age at MRI in years 11.3 (0.4) 11.3 (0.4) 0.03 (0.1, 0.2) 0.69
Corrected age at neurodevelopmental assessment in years 11.3 (0.4) 11.3 (0.4) 0.03 (0.1, 0.2) 0.69
IQ
Full scale 95.2 (12.4) 96.9 (13.4)5 1.6 (6.4, 3.1) 0.50
Verbal comprehension index 97.3 (11.5) 97.5 (13.7)5 0.2 (4.9, 4.4) 0.93
Perceptual reasoning index 94.5 (15.5) 96.8 (15.7) 2.3 (8.0, 3.4) 0.43
Wide range achievement test
Word reading standard score 98.5 (15.2) 97.1 (13.1) 1.5 (3.8, 6.7) 0.58
Sentence comprehension standard score 100.0 (13.9) 100.2 (15.9) 0.2 (5.7, 5.2) 0.94
Spelling standard score 96.9 (13.4) 95.5 (14.9) 1.4 (3.8, 6.6) 0.59
Math computation standard score 86.4 (14.1) 89.1 (15.4) 2.8 (8.2, 2.6) 0.31
Digit span
Forwards 7.3 (2.7)5 7.8 (2.8) 0.5 (1.5, 0.6) 0.38
Backwards 8.4 (2.5)5 8.4 (2.2) 0.1 (0.8, 0.9) 0.88
Beery VMI
Visual perception standard score 95.9 (11.6) 94.1 (13.9) 1.8 (2.9, 6.4) 0.45
Motor coordination standard score 92.1 (12.6) 90.4 (15.5) 1.7 (3.4, 6.8) 0.51
Movement ABC
Total standard score 9.2 (3.2)6 8.7 (2.9)5 0.5 (0.6, 1.7) 0.37
Manual dexterity standard score 8.1 (3.1)7 8.1 (2.9)5 0.03 (1.1, 1.2) 0.95
Aiming/catching standard score 10.3 (3.8)5 9.6 (0.5)5 0.7 (0.7, 2.0) 0.33
Balance standard score 10.1 (3.4)7 9.6 (2.6)5 0.6 (0.6, 1.7) 0.33
Cerebral palsy, n (%) 5 (7.9) 2 (3.7) OR 2.2, 95% CI 0.4, 12.1 0.35
Blindness, n (%) 0 (0.0) 0 (0.0) NA NA
Deafness, n (%) 1 (4.8)3 2 (9.5)3 OR 0.5, 95% CI 0.04, 5.7 0.56
Data are mean (SD), unless otherwise stated.
ABC, Assessment battery for children; CI, confidence interval; OR, odds ratio; MRI, magnetic resonance imaging; NA, not applicable; VMI, visual
motor integration test.
1Perinatal data were collected by chart review. Intraventricular hemorrhage was defined as described previously.40 Bronchopulmonary dysplasia
was defined as requirement for supplemental oxygen at 36 weeks’ postmenstrual age. Patent ductus arteriosus was defined as any case requiring
medical or surgical treatment. We did not have data on retinopathy of prematurity.
2Data on functional outcomes at 11 years of age (cognitive, academic, motor and behavioral outcomes) were collected as detailed previously.5
We did not collect any data on pubertal development.
3n = 21.
4n = 22.
5n = 1 with missing data.
6n = 3 with missing data.
7n = 2 with missing data.
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Cross-sectional analysis at age 11 years
Whole brain
Using FreeSurfer’s QDEC, there was little evidence that
cortical GM area, thickness and volume differed between
treatment groups. Using TBSS, there was little evidence
that FA, AD, RD, and MD differed between treatment
groups (that is, there were no vertices for QDEC and no
voxels for TBSS that differed between groups at P < 0.05,
multiple comparison corrected, hence no data can be
shown). Using the fixel-based analysis, there was evidence
that fiber cross-section was lower in the caffeine group
compared with the placebo group in 450 fixels (0.2% of
the total 210998 fixels), located predominantly in the
Figure 2. Results of the whole brain white matter microstructure analysis (fixel-based analysis) at 11 years of age. The fiber populations that had
a lower fiber cross-section in the caffeine group compared with the placebo group at P < 0.05, family-wise error rate (FWE) corrected, are shown
in red-yellow and overlaid on the study-specific fiber-orientation distribution template. These fibers were located mostly in the isthmus or
splenium of the corpus callosum, as well as the genu of the corpus callosum, and a very small number were in the left anterior limb of the
internal capsule. We have presented every second axial slice (in the range of the significant results). We have zoomed in on representative slices
to show the fiber orientation distribution in these slices, which shows that the significant results were located in single fiber regions. These results
are based on an analysis with n = 116 children (62 caffeine, 54 placebo), that is, one less than the total n = 117. One child was excluded from
this analysis as they did not complete the b = 3000 sec/mm2 diffusion sequence.
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corpus callosum isthmus or splenium subregions, and to
a lesser extent the genu, and a very small number were
located in the right anterior limb of the internal capsule
(Fig. 2). Only 6 fixels (0.0003% of the total fixels) in the
left anterior limb of the internal capsule had lower values
of the combined measure of fiber density and cross-sec-
tion in the caffeine group compared with the placebo
group (data not shown). There was little evidence that
fiber density differed between treatment groups. Results
were very similar in the three sensitivity analyses, but the
number of fixels increased slightly in each sensitivity anal-
ysis compared with the original analysis (Table S2).
Global and regional volumes and white matter
microstructure
Overall, there was little evidence that global brain vol-
umes (Fig. 3A), cortical, subcortical and deep nuclear
GM volumes and cerebellar volumes (Fig. 3B), and
microstructure and volume of primary sensorimotor and
cerebellar tracts (Fig. 3C) differed between treatment
groups. However, there was some evidence that volume
of the cerebellar tracts was lower in the caffeine group
compared with the placebo group (Fig. 3C). All these
results were very similar in the three sensitivity analyses
(data not shown).
There was some evidence that the corpus callosum was
thinner along much of its length in the caffeine group com-
pared with the placebo group (Fig. 4A), and this difference
was strongest in the rostral body and isthmus subregions
(Fig. 4A and B). There was also evidence that corpus callo-
sum area was smaller in the caffeine group compared with
the placebo group, particularly in the genu, rostral body,
and isthmus (Fig. 4B). Microstructure and volume of cor-
pus callosum tracts were generally similar between treat-
ment groups, although there was some evidence that RD
and MD in all subregions, and particularly the genu, were
higher in the caffeine group compared with the placebo
group (Fig. 4B). These differences in the corpus callosum
were generally very similar in the three sensitivity analyses;
if anything, the strength and magnitude of the differences
generally increased slightly after adjusting for bronchopul-
monary dysplasia (data not shown).
Longitudinal analysis
There was little evidence that the rate of change in brain
volumes varied between the caffeine and placebo groups
(Fig. 5).
There was some evidence that the area of the corpus
callosum increased more slowly in the caffeine group
compared with the placebo group, particularly in the
genu, rostral body, and isthmus (Fig. 6). There was also
evidence that AD, RD, and MD in the corpus callosum
tracts, particularly the genu, rostral body, and splenium,
decreased more slowly in the caffeine group compared
with the placebo group.
There was evidence that AD, RD, and MD (but not
FA) within the regions of interest decreased more slowly
in the caffeine group compared with the placebo group,
and the evidence was stronger for the superior regions
than the inferior regions (Fig. 7).
The results of the longitudinal analyses were very simi-
lar in the three sensitivity analyses (data not shown).
Discussion
Short-term neonatal caffeine treatment had little effect on
the volume or microstructure of most of the brain 11 years
later, except for the corpus callosum, which was smaller in
the caffeine group. Additionally, caffeine was weakly associ-
ated with brain volumetric development from term-equiva-
lent to 11 years of age, but caffeine was associated with
slower growth of the corpus callosum over time, and slower
decreases in WM diffusivities over time.
In our previous study, caffeine had little effect on brain
volumes, but benefitted WM microstructure by reducing
AD, RD, and MD in superior WM regions at the level of
the centrum semiovale compared with placebo, at term-
equivalent age.7 In the current study, we showed that
WM diffusivities decreased more slowly from term-
equivalent to 11 years of age in the caffeine group com-
pared with the placebo group, such that they generally
did not differ between treatment groups at age 11 years.
If we accept from previous studies that decreases in
diffusivities, particularly RD and MD, are expected and
beneficial during childhood development,32,33 the slower
Figure 3. Global and regional brain volumes and white matter microstructure, contrasted between treatment groups at 11 years of age. Mean
differences and P-values are from separate linear regression models for each MRI outcome, adjusted for age and sex of the child. The plots are
visual representations of the mean differences and 95% confidence intervals (CI). For bilateral outcomes, data from the left and right hemispheres
were analyzed in a single regression model, and results are presented as a single estimate for the difference for the two hemispheres, as there
was little evidence of group by hemisphere interactions. Units are cm3 for volumes and 9103 mm2/sec for diffusivities. SD = standard deviation.
The analyses are based on the total n = 117 (63 caffeine, 54 placebo) children, although some children are missing from some analyses because
their images had artifact which affected that particular analysis: an = 3 missing; bn = 2 missing; cn = 1 missing; dn = 5 missing; en = 4 missing.
The total numbers are lower for the tractography analyses (n = 116; 62 caffeine, 54 placebo) because one child in the caffeine group did not
have b = 3000 sec/mm2 diffusion images acquired and hence had to be excluded from the tractography analyses.
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Figure 4. Structure of the corpus callosum, contrasted between treatment groups at 11 years of age, based on the corpus callosum segmentation.
(A) Top: Mean thickness at each of 100 points along the corpus callosum; bottom: results of t-tests comparing thickness at each point between
treatment groups, with colors indicating P-values. (B) Data from the total corpus callosum and six sub-regions. Mean differences are from separate
linear regression models for each outcome, adjusted for age and sex of the child. The plots are visual representations of the mean differences and
95% confidence intervals (CI). Units are cm2 for area, cm for thickness and 9103 mm2/sec for diffusivities. SD = standard deviation. The analyses
are based on a total n = 116 (62 caffeine, 54 placebo) children, that is, one less than the total n = 117 children. One child from the caffeine group
was excluded from all the corpus callosum analyses because they had artefact on their structural image and because they did not have b = 3000 sec/
mm2 diffusion images acquired. Additional children were excluded from the corpus callosum tractography analysis, because their diffusion images
had artefact or structural abnormalities which affected that particular analysis: an = 2 missing; bn = 5 missing.
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Figure 5. Rates of change in brain volumes from term-equivalent age to 11 years of age, contrasted between treatment groups. Results are from
separate mixed effects models for each brain region, adjusted for sex of the child. The plots show the estimated means and 95% confidence intervals
(CI) per group for each time point and the rate of change between time points from the mixed models. The y-axes show the volumes and the x-axes
show age. Units are cm3 for volumes and years for age. The results are based on the total number of children who had usable MRI data at either
term-equivalent age or 11 years of age; for the intracranial cavity, total brain tissue, cerebrospinal fluid, deep nuclear gray matter and cerebellum,
n = 187 (n = 70 with term-equivalent data plus n = 117 with 11-year data); for the cortical gray matter, white matter and brainstem, n = 182
(n = 70 with term-equivalent data plus n = 112 with 11-year data); for the hippocampus, n = 179 (n = 62 with term-equivalent data plus n = 117
with 11-year data).
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decreases in diffusivities over time in the caffeine group
may suggest that any early benefits of caffeine treatment
on WM microstructure weaken over time.
However, caffeine appeared to influence corpus callo-
sum size, and microstructure to a lesser extent, at age
11 years. The smaller fiber cross-section, thickness and
Figure 6. Rates of change in the structure of the total corpus callosum and sub-regions from term-equivalent age to 11 years of age, contrasted
between treatment groups. Results are from separate mixed effects models for each corpus callosum region and parameter (area, thickness,
diffusion value or tract volume), adjusted for sex of the child. The plots show the estimated means and 95% confidence intervals (CI) per group for
each time point and the rate of change between time points from the mixed models. The y-axes show the parameters (area, thickness, diffusion
value or tract volume) and the x-axes show age. Units are cm for thickness, cm2 for area, cm3 for volumes, 9103 mm2/sec for diffusivities and
years for age. The results are based on the total number of children who had usable MRI data at either term-equivalent age or 11 years of age; for
the area measures, n = 144 (28 with term-equivalent data plus 116 with 11-year data); for the total tract diffusion and volume measures, n = 129
(20 plus 109); for the genu diffusion and volume measures, n = 137 (28 plus 109); for the rostral body diffusion and volume measures, n = 135
(26 plus 109); for the anterior mid body diffusion and volume measures, n = 133 (24 plus 109); for the posterior mid body diffusion and volume
measures, n = 134 (25 plus 109); for the isthmus diffusion and volume measures, n = 134 (25 plus 109); for the splenium diffusion and volume
measures, n = 137 (28 plus 109). FA, fractional anisotropy; AD, axial diffusivity; RD, radial diffusivity; MD, mean diffusivity.
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Figure 7. Rates of change in diffusion values in regions of interest from term-equivalent age to 11 years of age, contrasted between treatment
groups. Results are from separate mixed effects models for each region and parameter (FA, AD, RD, and MD), adjusted for sex of the child. The
plots show the estimated means and 95% confidence intervals (CI) per group for each time point and the rate of change between time points
from the mixed models. The y-axes show the parameters (FA, AD, RD, MD) and the x-axes show age. Results are combined across brain
hemispheres as there was negligible evidence that results differed by hemisphere. Units are 9103 mm2/sec for diffusivities and years for age.
The regions of interest were drawn on diffusion images from 28 infants at term-equivalent age.7 Of those 28 infants, 19 had MRI at 11 years of
age, and matching regions of interest were drawn on the 11-year diffusion images of these 19 children. These longitudinal analysis results are
based on the 28 infants with usable term-equivalent data and the 19 children with usable 11-year data. FA, fractional anisotropy; AD, axial
diffusivity, RD, radial diffusivity; MD, mean diffusivity.
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area in the caffeine group compared with the placebo
group found with both the fixel-based analysis and speci-
fic corpus callosum segmentation suggests the caffeine
group’s corpus callosum fibers are taking up less space.
The magnitude of the area difference (~half a square cen-
timeter) did not appear to be marginal, rather it is similar
to the magnitude of the difference in corpus callosum
area between very preterm and term-born children
reported previously.34 This finding could reflect axon loss
in the caffeine group, with the concurrent lack of differ-
ences in the fiber density measure from the fixel-based
analysis suggesting the remaining axons are still densely
packed.22 The finding could also reflect differences in
myelin between caffeine and placebo groups, but we can-
not be certain of this, because none of the techniques we
used specifically measure myelin. Future analyses using
MRI acquisitions and analysis techniques more sensitive
to myelin would be beneficial.35,36 Another possibility is
that the finding reflects more coherent alignment of axons
in the caffeine group. Because the precise cellular inter-
pretation is unclear, it is not possible for us to conclude
whether this difference would affect the ability of the cor-
pus callosum to transfer information and in turn affect
the cognitive or motor functioning of children treated
with caffeine. Our finding may line up with some studies
using animal models that reported adverse effects of caf-
feine on the developing brain.6 Regardless, the clinical
impact of this finding is likely to be negligible, given the
overall CAP trial clearly indicated that caffeine is associ-
ated with benefits, and no harm, to short- and long-term
health and neurodevelopmental outcomes for infants born
low birthweight.1–5
The mechanisms for caffeine’s beneficial neurological
effects have never been clear.2 Given that caffeine had no
clear benefits on brain structure at age 11 years, our
results do not support that brain structure at age 11 years
provides a link between caffeine and improved neurode-
velopmental outcomes, although brain-behavior relation-
ships require direct investigation in future. The early
improvements to WM microstructure in our previous
study7 may be more important than later brain develop-
ment for determining neurodevelopmental outcomes. It is
also possible that, rather than acting directly on the brain,
caffeine may act indirectly by reducing comorbidities such
as bronchopulmonary dysplasia and retinopathy of pre-
maturity,1,2 which themselves are strongly associated with
neurodevelopmental disabilities.37,38
The major strength of our study is that it is part of a
large randomized controlled trial, which is unlikely to be
replicated due to the clear clinical benefits of caffeine.
However, our study is limited in that only a small sample
of children from the CAP trial had MRI, reducing our
power to make inferences about the effects of caffeine on
the brain. MRI is also inherently limited in that it does
not directly measure brain structure and has too low res-
olution to identify alterations induced by caffeine at a cel-
lular level. Additional follow-up of the CAP children
would be beneficial, because until brain development has
plateaued in late adolescence or adulthood, any differ-
ences between treatment groups may not reflect benefits
or risks of caffeine, but may simply reflect normal varia-
tions during a period of rapid brain development. There
are many factors known to influence brain development,
which could confound our findings, including perinatal
medical factors, environmental and sociodemographic fac-
tors, and pubertal factors.30,31,39 Our results were inde-
pendent of three important factors that influence brain
development in preterm-born children: bronchopul-
monary dysplasia, major neonatal brain injuries and
maternal education level, which may relate to socioeco-
nomic status.
In conclusion, our study suggests there are no clear
benefits of caffeine on brain structure and development at
age 11 years that are detectable by MRI, although caffeine
may affect long-term corpus callosum development.
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